Catalyst’s Firdapse (amifampridine) Receives FDA’s Approval for Lambert-Eaton Myasthenic Syndrome

Shots:

• The approval is based on two clinical trial results assessing Firdapse vs PBO in 64 patients with Lambert-Eaton Myasthenic Syndrome
• The study measured Quantitative Myasthenia Gravis score (assessing muscle weakness) and demonstrated overall impression having effective results vs PBO
• Firdapse (amifampridine) is an EU approved drug in Dec 2009, indicated for symptomatic treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) and has also received FDA’s PT, BT & ODD

Click here to read full press release/ article | Ref: Catalyst | Image: Twitter